ストックスクリーナーアプリを入手
25.78
0.12%
0.03
アフターアワーズ：
25.78
前日終値:
$25.75
開ける：
$25.8
24時間の取引高:
405.27K
Relative Volume:
0.49
時価総額：
$1.43B
収益：
$2.50M
当期純損益:
$-131.12M
株価収益率:
-9.0676
EPS:
-2.8431
ネットキャッシュフロー:
$-112.73M
1週間 パフォーマンス:
+0.86%
1か月 パフォーマンス:
-2.72%
6か月 パフォーマンス:
-28.90%
1年 パフォーマンス:
+153.49%
1日の値動き範囲:
$25.49
$26.09
1週間の範囲:
$23.76
$26.09
52週間の値動き範囲:
$9.732
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
名前
Maze Therapeutics Inc
セクター
電話
(650) 850-5070
住所
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
25.78 | 1.43B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | 開始されました | Truist | Buy |
| 2026-03-10 | 開始されました | Mizuho | Outperform |
| 2025-12-04 | 開始されました | Wells Fargo | Overweight |
| 2025-11-14 | 開始されました | Raymond James | Outperform |
| 2025-09-02 | 開始されました | BTIG Research | Buy |
| 2025-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Maze Therapeutics Inc (MAZE) 最新ニュース
J.P. Morgan Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Cuts Target Price to $53 - Moomoo
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - AOL.com
Maze Therapeutics, Inc. Files Form 8-K with SEC: Company Details, Nasdaq Listing, and Contact Information - Minichart
100% Of This Maze Therapeutics Insider's Holdings Were Sold - 富途牛牛
Maze Therapeutics CEO Jason Coloma sells $50,388 in stock By Investing.com - Investing.com Australia
Maze Therapeutics Insider Sold Shares Worth $393,354, According to a Recent SEC Filing - Moomoo
Maze Therapeutics CEO Jason Coloma sells $50,388 in stock - Investing.com
CEO Coloma trusts trim 1,938 Maze Therapeutics (MAZE) shares under 10b5-1 plan - Stock Titan
Maze Therapeutics (MAZE) CMO sells 15,000 shares, exercises options - Stock Titan
Maze Therapeutics, Inc. (MAZE) reports Q1 loss, beats revenue estimates - MSN
HighVista Strategies Sells Maze Therapeutics Shares in Q1 2026News and Statistics - IndexBox
HighVista Strategies Sells Shares of Maze Therapeutics Amid Stock Surge - Intellectia AI
JP Morgan Maintains Maze Therapeutics (MAZE) Overweight Recommendation - MSN
Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts - Yahoo Finance
Wall Street Zen Upgrades Maze Therapeutics (NASDAQ:MAZE) to Hold - MarketBeat
Rule 144 notice: MAZE (NASDAQ: MAZE) lists Common share lots and broker - Stock Titan
Janus Henderson (MAZE) discloses 2.86M shares, a 5.8% stake - Stock Titan
Maze Therapeutics stock falls despite strong phase 2 kidney drug data for MZE829 - MSN
MAZE Stock Price, Quote & Chart | MAZE THERAPEUTICS INC (NASDAQ:MAZE) - ChartMill
Maze Therapeutics2026 Funding Rounds & List of Investors - Tracxn
A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $48 to $110 - Moomoo
[EFFECT] Maze Therapeutics, Inc. SEC Filing - Stock Titan
Maze Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Maze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline - TipRanks
LifeSci Capital Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Maze Therapeutics 1Q License Rev $20M >MAZE - Moomoo
Maze Therapeutics Expects Will Fund Ops Into 2029 Based on Its Current Business Plan >MAZE - Moomoo
Maze Therapeutics Inc. unveils quarterly results and updates on operational advances - Traders Union
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Maze Therapeutics 1Q Loss/Shr 45c >MAZE - Moomoo
Maze Therapeutics, Inc. 1Q 2026: Revenue $20M, EPS $(0.45) — 10-Q Summary - TradingView
Maze Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Maze Therapeutics (NASDAQ: MAZE) trims Q1 loss as cash, pipeline and Shionogi milestone grow - Stock Titan
Maze Therapeutics (NASDAQ: MAZE) Q1 2026 loss narrows on milestone revenue - Stock Titan
[POS AM] Maze Therapeutics, Inc. SEC Filing - Stock Titan
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights - The Manila Times
What date does Maze Therapeutics, Inc.'s (MAZE) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
A Look At Maze Therapeutics (MAZE) Valuation After Recent Share Price Weakness - Yahoo Finance
TradingKey - TradingKey
Number of shareholders of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Assessing Maze Therapeutics (MAZE) Valuation After Mixed Returns And A Premium Price To Book Multiple - Sahm
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Exploring a Potential 149.49% Upside in Biotech - DirectorsTalk Interviews
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials - The Motley Fool
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials - The Motley Fool
Maze Therapeutics (MAZE) CSBO exercises options for 14,305 shares - Stock Titan
Director Charles Homcy gifts 7,422 Maze Therapeutics (MAZE) shares - Stock Titan
Maze Therapeutics (MAZE) CSBO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $190,275.00 in Stock - MarketBeat
MAZE SEC FilingsMaze Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
After plunging 30.8% in 4 weeks, here's why the trend might reverse for Maze Therapeutics, Inc. (MAZE) - MSN
Maze Therapeutics (NASDAQ: MAZE) details 2026 proxy, board slate and executive pay - Stock Titan
Maze Therapeutics Inc (MAZE) 財務データ
収益
当期純利益
現金流量
EPS
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):